Prothena Stock (NASDAQ:PRTA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$16.80

52W Range

$15.52 - $55.89

50D Avg

$20.96

200D Avg

$24.72

Market Cap

$906.74M

Avg Vol (3M)

$451.31K

Beta

0.16

Div Yield

-

PRTA Company Profile


Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

173

IPO Date

Dec 18, 2012

Website

PRTA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Collaboration$91.32M$13.86M$139.83M
License$50.00K--
US Rights and Global Rights-$85.30M-
Collaboration Program, US Rights-$13.90M$24.90M

Fiscal year ends in Dec 23 | Currency in USD

PRTA Financial Summary


Dec 23Dec 22Dec 21
Revenue$91.37M$53.91M$200.58M
Operating Income$-191.04M$-131.56M$71.97M
Net Income$-147.03M$-116.95M$66.97M
EBITDA$-190.11M$-131.56M$71.97M
Basic EPS$-2.76$-2.47$1.51
Diluted EPS$-2.76$-2.47$1.38

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 23Feb 15, 24 | 11:53 PM
Q4 22Feb 24, 23 | 12:33 AM
Q4 21Feb 17, 22 | 10:21 PM

Peer Comparison


TickerCompany
DICEDICE Therapeutics, Inc.
PLRXPliant Therapeutics, Inc.
NUVLNuvalent, Inc.
CGEMCullinan Oncology, Inc.
KNSAKiniksa Pharmaceuticals, Ltd.
VRDNViridian Therapeutics, Inc.
VTYXVentyx Biosciences, Inc.
STOKStoke Therapeutics, Inc.
SCPHscPharmaceuticals Inc.
IMCRImmunocore Holdings plc
MCRBSeres Therapeutics, Inc.
ONCYOncolytics Biotech Inc.
ACLXArcellx, Inc.
ETNB89bio, Inc.
PCVXVaxcyte, Inc.
MISTMilestone Pharmaceuticals Inc.
LIFEaTyr Pharma, Inc.
MDGLMadrigal Pharmaceuticals, Inc.